Published on 22 Jan 2024 on Insider Monkey via Yahoo Finance
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% (Institutional Shares) in the quarter compared to a 6.96% gain for the Russell 3000 Health Care Index and an 11.69% increase for the S&P 500 Index. For the full year, the fund increased 6.42%, compared to 2.87% and 26.29% returns for the indexes, respectively. In addition, please check the fund’s top five holdings to know its best picks in 2023.
Baron Health Care Fund featured stocks such as Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the fourth quarter 2023 investor letter. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a multi-platform biotechnology company. On January 19, 2024, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock closed at $26.56 per share. One-month return of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) was -11.76%, and its shares gained 29.88% of their value over the last 52 weeks. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has a market capitalization of $2.395 billion.
Baron Health Care Fund stated the following regarding Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in its fourth quarter 2023 investor letter: